LifeMD, Inc. — a telehealth company that also operates the Rex MD and ShapiroMD brands — has been the subject of a news investigation, a completed class action settlement, a pending securities case and an open attorney investigation, all within roughly twelve months. Those four matters are frequently described interchangeably. Below, eight claims currently in circulation are set against the documented record. Each entry states only what the record shows.
Table of Contents
- there is a LifeMD class action over GLP-1 prescribing that patients can jo
- the LifeMD and RexMD privacy settlement is still accepting claims
- the LifeMD settlement was a $1.1 million fund divided among claimants
- the LifeMD privacy case was dismissed
- the FDA sanctioned LifeMD over GLP-1 marketing
- LifeMD restated its financial statements
- the 2021 securities case established that LifeMD executives had an FTC his
- nothing involving LifeMD is currently open
- How we checked
- What remains unproven
Claim: there is a LifeMD class action over GLP-1 prescribing that patients can join
Verdict: FALSE
No consumer class action over LifeMD’s GLP-1 prescribing has been identified. No class has been certified, no settlement exists and there is no claim form. The July 20, 2026 report by the health-news outlet STAT was sourced to interviews with five former employees and to two lawsuits filed by former senior leaders of the company. Those two lawsuits are employment disputes between LifeMD and former executives, not patient claims. LifeMD denies the allegations; its chief executive, Justin Schreiber, told STAT the company’s objective “has not been to run a pill mill” and that it has “actually taken the opposite position.”
Claim: the LifeMD and RexMD privacy settlement is still accepting claims
Verdict: FALSE
The deadline to submit a claim, request exclusion or object was September 22, 2025. A fairness hearing was held on September 30, 2025 and the court entered an order granting final approval the same day. The court-authorised settlement website states that distribution of benefits to timely, valid claimants began on January 21, 2026. No late-claim process has been announced.
Claim: the LifeMD settlement was a $1.1 million fund divided among claimants
Verdict: MISLEADING
The figure of approximately $1.1 million appears in LifeMD’s Form 10-Q for the quarter ended September 30, 2025 as the company’s estimated settlement liability — an accounting estimate, not a fund. The settlement agreement placed no aggregate cap on class-member benefits, so benefits were not divided pro rata. A timely, valid claimant could elect $10 in cash or a $25 voucher for LifeMD or RexMD products or services, valid two years. The court separately awarded $750,000 in attorneys’ fees and expenses and $2,500 to each of two class representatives, which the notice stated would be paid separately from class-member benefits.
Claim: the LifeMD privacy case was dismissed
Verdict: NEEDS CONTEXT
Two dismissals occurred and they mean opposite things. Matthew Marden filed in the U.S. District Court for the Southern District of New York on August 23, 2023; LifeMD moved to dismiss the amended complaint on March 4, 2024; the parties mediated on July 12, 2024; and on November 1, 2024 the plaintiffs voluntarily dismissed that action without prejudice. On November 25, 2024 the claims were refiled in the District Court of Clark County, Nevada as W.M.F. & Matthew Marden v. LifeMD, Inc., No. A-24-906800-C. That case settled and was dismissed with prejudice after final approval on September 30, 2025.
Claim: the FDA sanctioned LifeMD over GLP-1 marketing
Verdict: UNSUPPORTED
No FDA warning letter to LifeMD has been identified. The FDA sent warning letters to more than 50 compounders and manufacturers in September 2025, to 30 telehealth companies on March 3, 2026, and to a further 25 in June 2026, in each case over claims made about compounded semaglutide and tirzepatide. Those actions concerned marketing statements about compounded drugs. Separately, LifeMD told investors on August 5, 2026 that roughly 95% of its new weight-management patients start on branded GLP-1 therapies and that its transition away from compounded versions is effectively complete.
Claim: LifeMD restated its financial statements
Verdict: PARTLY ACCURATE
In November 2025 LifeMD postponed its third-quarter earnings release after identifying corrections to how it had recognised revenue across 2023, 2024 and the first half of 2025. The cumulative effect was approximately $4.6 million, or about 1.4% of the revenue reported over those periods. The company characterised the change as a revision rather than a restatement and said it did not materially affect cash flow or performance against guidance.
📨 Get Free News Stories Alerts
Free · No spam · Unsubscribe anytime
Claim: the 2021 securities case established that LifeMD executives had an FTC history
Verdict: FALSE
Owens v. LifeMD, Inc. was filed in the Southern District of New York in April 2021 and alleged, among other things, that the company had not disclosed that several executives were previously associated with an entity the FTC had pursued. The case was voluntarily dismissed on May 18, 2021, roughly one month after filing. Its allegations were never tested and no court made any finding on them.
Claim: nothing involving LifeMD is currently open
Verdict: FALSE
Two matters are open. Johnston v. LifeMD, Inc., a securities class action filed August 27, 2025 in the Eastern District of New York, alleges the company made materially false or misleading statements about its 2025 outlook, in particular by raising full-year guidance in May 2025 without properly accounting for rising customer-acquisition costs in its RexMD segment; LifeMD cut that guidance on August 5, 2025 and the stock fell roughly 45% the following day. Separately, attorneys are investigating potential cases against LifeMD for alleged privacy violations in California, concerning whether intake questionnaires on LifeMD and its Rex MD and ShapiroMD brands passed visitors’ answers to third-party advertising networks before those visitors accepted the terms or created an account. No complaint has been filed in the California matter and no class has been certified.
How we checked
Each entry above rests on one or more of the following primary or first-hand sources:
- The order granting final approval entered September 30, 2025 in W.M.F. & Matthew Marden v. LifeMD, Inc., No. A-24-906800-C, District Court of Clark County, Nevada, and the settlement agreement signed April 29–30, 2025.
- The court-authorised settlement website, which states the claim deadline, the final approval date and the January 21, 2026 start of distribution.
- LifeMD, Inc. periodic filings with the SEC, including the Form 10-Q for the quarter ended September 30, 2025 and the company’s second-quarter 2026 results announced August 5, 2026.
- Published FDA warning-letter actions dated September 2025, March 3, 2026 and June 2026.
- The Federal Trade Commission’s action against NextMed, July 2025, and its final order of December 2025; and the complaint filed July 29, 2026 by the FTC with the State of Utah and Los Angeles County against Hims & Hers Health in the Northern District of California.
- STAT, “LifeMD, a popular telehealth firm, put profits over patient safety, ex-workers say,” July 20, 2026, for the former employees’ accounts and the company’s response.
Docket and settlement detail for both LifeMD matters is maintained by OpenClassActions.com at LifeMD & RexMD Privacy Settlement Closed: Payment Status and Did LifeMD Rush GLP-1 Prescriptions? What Ex-Workers Say, and the criteria for the open California matter at the LifeMD data privacy investigation page.
What remains unproven
- Every allegation in the STAT report is unproven. LifeMD denies it. No court or regulator has made any finding against the company on it.
- The allegations in the two lawsuits brought by former senior leaders are untested.
- The allegations in Johnston v. LifeMD, Inc. are unproven. There has been no finding of liability.
- The allegations in the Nevada privacy case were denied and were never decided. The settlement is not an admission of liability.
- The California matter is an attorney investigation. No complaint has been filed, no class has been certified, and nothing has been proven.
Questions people ask
Is there a LifeMD class action over GLP-1 prescribing?
No consumer class action over LifeMD GLP-1 prescribing has been identified. No class has been certified and there is no claim form. The July 20, 2026 STAT report was sourced to five former employees and to two lawsuits brought by former senior leaders, which are employment disputes. LifeMD denies the allegations.
Can I still claim in the LifeMD and RexMD privacy settlement?
No. The claim, exclusion and objection deadline was September 22, 2025. Final approval was entered September 30, 2025 and distribution to timely, valid claimants began January 21, 2026.
Was the LifeMD settlement a $1.1 million fund?
No. Approximately $1.1 million was the estimated settlement liability LifeMD reported in its Form 10-Q for the quarter ended September 30, 2025. The settlement agreement placed no aggregate cap on class-member benefits. Claimants could elect $10 in cash or a $25 voucher.
Has the FDA taken action against LifeMD?
No FDA warning letter to LifeMD has been identified. The FDA sent letters to 30 telehealth companies on March 3, 2026 and to 25 more in June 2026 over claims about compounded semaglutide and tirzepatide.
Is any LifeMD matter still open?
Two. A securities class action, Johnston v. LifeMD, Inc., filed August 27, 2025 in the Eastern District of New York. And an attorney investigation into potential California privacy claims, in which no complaint has been filed and no class has been certified.
News Accurate is not a law firm, not a claims administrator, and is not affiliated with any company named here. This article is general information, not legal, medical or investment advice. Where a matter is described as alleged, it has not been proven.